News | June 05, 2021
Jubilant Pharmova posts Q4FY21 consolidated PAT of Rs. 213.90 Cr
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
Aurobindo has one of the most enduring generics ecosystems among peers
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Adjusted PAT declined 18.8% YoY
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
Subscribe To Our Newsletter & Stay Updated
